[1]马新豫.黄芪联合多巴酚丁胺及酚妥拉明治疗慢性肺源性心脏病顽固性心力衰竭疗效观察[J].新乡医学院学报,2021,38(2):133-136.[doi:10.7683/xxyxyxb.2021.02.007]
　MA Xinyu.Effect of astragalus membranaceus combined with dobutamine and phentolamine in the treatment of chronic pulmonary heart disease with refractory heart failure[J].Journal of Xinxiang Medical University,2021,38(2):133-136.[doi:10.7683/xxyxyxb.2021.02.007]
点击复制

黄芪联合多巴酚丁胺及酚妥拉明治疗慢性肺源性心脏病顽固性心力衰竭疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年2
页码:
133-136
栏目:
临床研究
出版日期:
2021-02-05

文章信息/Info

Title:
Effect of astragalus membranaceus combined with dobutamine and phentolamine in the treatment of chronic pulmonary heart disease with refractory heart failure
作者:
马新豫
（驻马店市中心医院心内一科,河南　驻马店　463000）
Author(s):
MA Xinyu
（Department of Cardiology,the Central Hospital of Zhumadian，Zhumadian 463000，Henan Province，China）
关键词:
黄芪; 多巴酚丁胺; 酚妥拉明; 慢性肺源性心脏病; 顽固性心力衰竭
Keywords:
astragalus; dobutaminephentolaminechronic pulmonary heart diseaserefractory heart failure
分类号:
R541.5
DOI:
10.7683/xxyxyxb.2021.02.007
文献标志码:
A
摘要:
目的　探讨黄芪联合多巴酚丁胺及酚妥拉明治疗慢性肺源性心脏病顽固性心力衰竭的临床疗效。方法　选择2016年7月至2017年8月驻马店市中心医院收治的68例慢性肺源性心脏病顽固性心力衰竭患者为研究对象，将患者随机分为对照组和观察组，每组34例。对照组患者给予抗感染、氧气治疗、改变通气、纠正心力衰竭等常规治疗，观察组患者在对照组治疗的基础上加用黄芪、多巴酚丁胺及酚妥拉明，2组患者均治疗7 d。观察2组患者的治疗效果、不良反应发生情况、住院时间、呼吸困难与发绀症状改善情况及治疗前后肺动脉收缩压（SPAP）、动脉血氧分压（PaO2）、血氧饱和度（SaO2）、第1秒用力呼气容积(FEV1)、心脏射血分数(EF)。结果　观察组患者住院时间显著短于对照组，呼吸困难、发绀的发生率低于对照组（P<0.01）。治疗前2组患者spap、pao>2、SaO2、FEV1、EF比较差异均无统计学意义（P>0.05）；治疗后，2组患者SPAP较治疗前显著降低，PaO2、SaO2、FEV1、EF较治疗前显著升高（P<0.05）。治疗后观察组患者spap显著低于对照组，pao>2、SaO2、FEV1、EF显著高于对照组（P2=6.928，P<0.05）。对照组和观察组患者不良反应发生率分别为38.24%（13/34）和14.71%（5/34）；观察组患者不良反应发生率显著低于对照组（χ2=4.837,P<0.05）。结论　黄芪联合多巴酚丁胺及 酚妥拉明治疗慢性肺源性心脏病顽固性心力衰竭具有显著效果。undefinedundefined
Abstract:
Objective　To investigate the clinical efficacy of astragalus membranaceus combined with dobutamine and phentolamine in the treatment of chronic pulmonary heart disease and refractory heart failure.Methods　　A total of 68 patients with chronic pulmonary heart disease with refractory heart failure admitted to the Central Hospital of Zhumadian from July 2016 to August 2017 were selected as the study objects,and all the patients were randomly divided into control group and observation group,with 34 patients in each group.Patients in the control group were given routine treatments such as anti-infection,oxygen therapy,change of ventilation,correction of heart failure,and so on.Based on the treatment of the control group,Patients in the observation group were given astragalus,dobutamine and phentolamine.The patients in both groups were treated for seven days.The therapeutic effect,adverse events,hospital stay,improvement of dyspnea and cyanosis,and pulmonary arterial systolic pressure (SPAP),arterial oxygen partial pressure (PaO2),blood oxygen saturation (SaO2),forced expiratory volume in one second (FEV1),and cardiac ejection fraction (EF) in the two groups before and after treatment were observed.Results　The hospital stays in the observation group was significantly shorter than that in the control group,and the incidence of dyspnea and cyanosis was lower than that in the control group (P<0.01).There was no significant difference in the SPAP,PaO2,SaO2,FEV1 and EF between the two groups before treatment (P>0.05).After treatment,the SPAP of patients in the two groups was significantly lower than that before treatment,the PaO2,SaO2,FEV1 and EF were significantly higher than that before treatment (P<0.05).After treatment,the SPAP of patients in the observation group was significantly lower than that in the control group,the PaO2,SaO2,FEV1 and EF were significantly higher than those in the control group (P<0.05).The total effective rate in the control group and the observation group was 64.70% (22/34) and 91.78% (31/34).The total effective rate in the observation group was significantly higher than that in the control group (χ2=6.928,P<0.05).The incidence of adverse reactions in the control group and the observation group was 38.24% (13/34) and 14.71% (5/34),respectively.The incidence of adverse reactions in the observation group was lower than that in the control group (χ2=4.837,P<0.05).Conclusion　Astragalus membranaceus combined with dobutamine and phentolamine has a significant effect in the treatment of chronic pulmonary heart disease with refractory heart failure.

参考文献/References:

［1］　卜丽娜,宋爱玲,贾卫红,等.法舒地尔治疗老年慢性肺源性心脏病临床疗效及其机制的随机对照研究［J］.中国全科医学,2017,20(5):538-542.
［2］　刘建文,郭东.丹红注射液联合卡托普利治疗慢性肺源性心脏病疗效及对NT-proBNP水平的影响［J］.中国老年学杂志,2019,39(11):2589-2591.
［3］　中华医学会.临床诊疗指南呼吸病学分册［M］.北京：人民卫生出版社，2009：6-8.
［4］　BERTHELOT E,BAUER F,EICHER J C,et al.Pulmonary hypertension in chronic heart failure:definitions,advances,and unanswered issues［J］.ESC Heart Fail，2018，5(5):755-763.
［5］　燕学波,蒋德军,耿丽丹，等.老年慢性肺源性心脏病合并右侧心力衰竭加用心脉隆注射液治疗的效果［J］.实用医药杂志,2019,36(7):615-616.
［6］　王辉.肺心病伴顽固性心力衰竭的临床治疗研究［J］.基层医学论坛,2016,20(13):1769-1770.
［7］　李翔,郑文武,高毅滨.米力农与洋地黄治疗慢性肺源性心脏病心力衰竭急性加重期患者的比较观察［J］.中国循证心血管医学杂志,2018,10(5):591-593.
［8］　DZYURICH T A,CHESNIKOVA A I,TERENTYEV V P,et al.Evaluation of diagnostic criteria of heart failure in patients with atrial fibrillation and chronic obstructive pulmonary disease［J］.Kardiologiia，2019，59(10S):4-12.
［9］　郝轩轩,崔琳,王幼平，等.黄芪治疗心力衰竭的研究进展［J］.中西医结合心脑血管病杂志,2018,16(12):1666-1668.
［10］　TAVARES-SILVA M,ALAA M,LEITE S,et al.Dose-response head-to-head comparison of inodilators dobutamine,milrinone,and levosimendan in chronic experimental pulmonary hypertension［J］.J Cardiovasc Pharmacol Ther，2017，22(5):485-495.
［11］　夏科君,单淑琴,赵蓓，等.酚妥拉明联合呋塞米对肺炎伴心力衰竭患儿EDV、ESV水平及心电图的影响［J］.中国生化药物杂志,2017,18(4):278-280.
［12］　雷伟,崔巍,唐露，等.酚妥拉明联合阿拉明治疗小儿肺炎合并心力衰竭的临床效果分析［J］.陕西医学杂志,2016,45(8):1082-1083.

相似文献/References:

[1]刘巨源　陈永凤　郭　萍　高新平　路成吉.黄芪丹参甘草等中药对大鼠肺纤维化的影响[J].新乡医学院学报,1999,16(04):292.
[2]李红叶,岳伟 刘瑞芝.维生素A与黄芪联合治疗小儿反复呼吸道感染[J].新乡医学院学报,2000,17(01):060.
[3]汪裕荣.灯盏花注射液治疗急性脑梗死128例[J].新乡医学院学报,2002,19(01):050.
[4]孛长文,任明芬,王鹩鹏.黄芪对老年心绞痛患者血流变学的影响[J].新乡医学院学报,2002,19(01):039.
[5]张建华.多巴胺联合多巴酚丁胺治疗新生儿窒息后循环障碍32例[J].新乡医学院学报,2003,20(05):340.
[6]周永生,刘军.黄芪注射液治疗脑梗死60例疗效观察[J].新乡医学院学报,2003,20(05):357.
[7]张建华.多巴胺联合多巴酚丁胺治疗新生儿窒息后循环障碍32 例[J].新乡医学院学报,2003,20(05):340.
[8]潘艳子,陈新政,马宝梅.黄芪对原发性肾小球肾炎患者血清白细胞介素１７和肿瘤坏死因子α水平的影响[J].新乡医学院学报,2015,32(12):1098.
[9]郭珂一,李清华,柯尊记.黄芪散对阿尔茨海默病的防治作用研究进展[J].新乡医学院学报,2020,37(5):489.[doi:10.7683/xxyxyxb.2020.05.021]
[10]吴　娇,王　聪.黄芪的化学成分及药理作用研究进展[J].新乡医学院学报,2018,35(9):755.[doi:10.7683/xxyxyxb.2018.09.002]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(2):755.[doi:10.7683/xxyxyxb.2018.09.002]

更新日期/Last Update: 2021-02-05